- Home
- SPTN vs AUTL Comparison
SPTN vs AUTL Comparison
Compare SPTN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPTN
- AUTL
- Stock Information
- Founded
- SPTN 1917
- AUTL 2014
- Country
- SPTN United States
- AUTL United Kingdom
- Employees
- SPTN 17000
- AUTL N/A
- Industry
- SPTN Food Distributors
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPTN Consumer Discretionary
- AUTL Health Care
- Exchange
- SPTN Nasdaq
- AUTL Nasdaq
- Market Cap
- SPTN 630.9M
- AUTL 590.8M
- IPO Year
- SPTN N/A
- AUTL 2018
- Fundamental
- Price
- SPTN $18.69
- AUTL $2.17
- Analyst Decision
- SPTN Hold
- AUTL Strong Buy
- Analyst Count
- SPTN 1
- AUTL 3
- Target Price
- SPTN $20.00
- AUTL $10.20
- AVG Volume (30 Days)
- SPTN 248.1K
- AUTL 1.1M
- Earning Date
- SPTN 02-12-2025
- AUTL 03-13-2025
- Dividend Yield
- SPTN 4.71%
- AUTL N/A
- EPS Growth
- SPTN 9.92
- AUTL N/A
- EPS
- SPTN 1.33
- AUTL N/A
- Revenue
- SPTN $9,532,883,000.00
- AUTL $10,091,000.00
- Revenue This Year
- SPTN N/A
- AUTL $851.83
- Revenue Next Year
- SPTN $2.15
- AUTL $224.65
- P/E Ratio
- SPTN $14.06
- AUTL N/A
- Revenue Growth
- SPTN N/A
- AUTL 82.71
- 52 Week Low
- SPTN $17.30
- AUTL $2.07
- 52 Week High
- SPTN $23.00
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- SPTN 56.59
- AUTL 41.81
- Support Level
- SPTN $17.77
- AUTL $2.11
- Resistance Level
- SPTN $18.66
- AUTL $2.26
- Average True Range (ATR)
- SPTN 0.40
- AUTL 0.12
- MACD
- SPTN 0.11
- AUTL 0.01
- Stochastic Oscillator
- SPTN 96.19
- AUTL 27.78
About SPTN SpartanNash Company
SpartanNash Co is a food solutions company that delivers the ingredients. Its principal business activities include, distributing grocery products to a diverse group of independent and chain retailers, its corporate-owned retail stores, and U.S. military commissaries and exchanges; as well as operating a fresh produce distribution network and the Our Family private label brand. The company operates in two segments: Retail and Wholesale. Majority of the revenue is earned from its Wholesale segment which uses a multi-channel sales approach to distribute national brand and private brand products to independent retailers, national accounts, food service distributors, e-commerce providers, and the Company's corporate owned retail stores.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.